Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers

Feng, Qiang; Sun, B.Z.; Xue, Tianyi; Li, Rong; Lin, Chao; Gao, Yongjian; Sun, Liqun; Yang, Zhuo; Wang, Dongxu

doi:10.3389/fimmu.2022.1025608

Cited by 5 publications

(3 citation statements)

References 92 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of anti-angiogenic or targeted therapy drugs with immunotherapy compounds may again enhance the susceptibility of immune cold tumors to immunotherapy, as seen in KEYNOTE-811 trial investigating the combination of trastuzumab and pembrolizumab [ 43 ]. Novel therapeutic strategies might also try to induce response by increasing the frequency of tumor-specific T cells with personalized approaches such as CAR T cell therapy [ 70 ]. Future years might shed some light on optimizing treatment strategies for biomarker-negative patient cohorts.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer

Puhr

Reiter

Preusser

et al. 2023

Cancers

View full text Add to dashboard Cite

The overall survival expectancy of localized gastroesophageal cancer patients still remains under 5 years despite advances in neoadjuvant and adjuvant treatment strategies in recent years. For almost a decade, immunotherapy has been successfully implemented as a first-line treatment for various oncological diseases in advanced stages. In the case of advanced gastroesophageal cancer, 2021 witnessed several approvals of immune checkpoint inhibitor therapies by different authorities. Although it is still a debate whether this treatment should be restricted to a certain subgroup of patients based on biomarker selection, immunotherapy agents are making remarkable steps in resectable settings as well. The Checkmate-577 study demonstrated significant benefits of nivolumab as an adjuvant treatment for resectable esophageal and gastroesophageal junction tumors and thereby obtained approvals both from U.S. American and European authorities. First results of further potential practice-changing clinical trials are expected in 2023, which might change the treatment armamentarium for resectable gastroesophageal cancers significantly. This review aims to demonstrate the advances of immunotherapy and targeted therapies in treatment of localized gastric, gastroesophageal junction and esophageal tumors and gives a short summary on promising ongoing clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer

Puhr

Reiter

Preusser

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The scFv is able to bind tightly to the target antigen, enabling specific recognition by the CAR-T cell (45). Once CAR-T cells recognize the target antigen, signaling domains within the CAR, such as CD3ζ, will be activated, triggering an intracellular signaling cascade (46). This process is similar to the activation of a normal T-cell receptor upon binding to an antigen (47).…”

Section: Targeted Killing Mechanism Of Car-t Cellsmentioning

confidence: 99%

CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Sun,

Shi,

et al. 2024

Mol Med Rep

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-T cell therapy is an innovative approach to immune cell therapy that works by modifying the T cells of a patient to express the CAR protein on their surface, and thus induce their recognition and destruction of cancer cells. CAR-T cell therapy has shown some success in treating hematological tumors, but it still faces a number of challenges in the treatment of solid tumors, such as antigen selection, tolerability and safety. In response to these issues, studies continue to improve the design of CAR-T cells in pursuit of improved therapeutic efficacy and safety. In the future, CAR-T cell therapy is expected to become an important cancer treatment, and may provide new ideas and strategies for individualized immunotherapy. The present review provides a comprehensive overview of the principles, clinical applications, therapeutic efficacy and challenges of CAR-T cell therapy. Contents 1. Introduction 2. CAR-T cell structure 3. Targeted killing mechanism of CAR-T cells 4. CAR-T cell therapy treatment process 5. Clinical utilization of CAR-T cell therapy 6. Side effects and clinical challenges of CAR-T cell therapy 7. CAR-T cell therapy representative drugs 8.

show abstract

“…A final novel immune-based therapeutic approach with potential in the field of gastroesophageal malignancies is Chimeric antigen receptor T-cell (CAR) therapy. A CAR is a manufactured receptor introduced to T cells using viral vectors, and allows the T cell to identify and target certain malignancy-related antigens [72]. The CAR incorporates an extracellular domain which serves to identify the antigens in addition to transmembrane and intracellular signaling domains allowing functionality independent of major histocompatibility molecules.…”

Section: Looking Forward-the Future Of Immunotherapy In Gastroesophag...mentioning

confidence: 99%

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies

Lynch,

Duffy,

Kelly

2023

Cancers

View full text Add to dashboard Cite

Background: Gastroesophageal cancers (GECs) carry considerable morbidity and mortality, and demonstrate geographical histological variances in addition to molecular heterogeneity. Consequently, the immunogenicity of the different subtypes, which can predict the likelihood of immunotherapy response, can vary. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of many cancer types over the past decade but has been slower to gain a foothold in the treatment paradigm of GECs. Methods: This article reviews the existing evidence and use approvals for immunotherapies and immune-based treatments in GECs, in the neoadjuvant, adjuvant and metastatic disease settings. The challenges of and limitations to ICI application in current clinical practice are examined. Ongoing clinical trials and future directions of research are also considered. Conclusion: ICI therapy has become an established treatment option within GECs, both perioperatively and in advanced disease. However, nuances in terms of its use are not yet fully understood. Ongoing research proposes to broaden the application of immunotherapies in GECs with the potential to continue to improve outcomes.

show abstract

Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers

Cited by 5 publications

References 92 publications

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer

CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies

Contact Info

Product

Resources

About